Literature DB >> 10595537

Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.

V Gigoux1, B Maigret, C Escrieut, S Silvente-Poirot, M Bouisson, J A Fehrentz, L Moroder, D Gully, J Martinez, N Vaysse, A D Fourmy.   

Abstract

The knowledge of the binding sites of G protein-coupled cholecystokinin receptors represents important insights that may serve to understand their activation processes and to design or optimize ligands. Our aim was to identify the amino acid of the cholecystokinin-A receptor (CCK-AR) binding site in an interaction with the sulfate of CCK, which is crucial for CCK binding and activity. A three-dimensional model of the [CCK-AR-CCK] complex was built. In this model, Arg197 was the best candidate residue for a ionic interaction with the sulfate of CCK. Arg197 was exchanged for a methionine by site-directed mutagenesis. Wild-type and mutated CCK-AR were transiently expressed in COS-7 cells for pharmacological and functional analysis. The mutated receptor on Arg197 did not bind the agonist radioligand 125I-BH-[Thr, Nle]-CCK-9; however, it bound the nonpeptide antagonist [3H]-SR27,897 as the wild-type receptor. The mutant was approximately 1,470- and 3,200-fold less potent than the wild-type CCK-AR to activate G proteins and to induce inositol phosphate production, respectively. This is consistent with the 500-fold lower potency and 800-fold lower affinity of nonsulfated CCK relative to sulfated CCK on the wild-type receptor. These data, together with those showing that the mutated receptor failed to discriminate nonsulfated and sulfated CCK while it retained other pharmacological features of the CCK-AR, strongly support an interaction between Arg197 of the CCK-AR binding site and the sulfate of CCK. In addition, the mutated CCK-AR resembled the low affinity state of the wild-type CCK-AR, suggesting that Arg197-sulfate interaction regulates conformational changes of the CCK-AR that are required for its physiological activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595537      PMCID: PMC2144185          DOI: 10.1110/ps.8.11.2347

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  31 in total

1.  Hormonal polypeptides of the upper intestine.

Authors:  V Mutt; E Jorpes
Journal:  Biochem J       Date:  1971-12       Impact factor: 3.857

2.  Interactions of COOH-terminal fragments of cholecystokinin with receptors on dispersed acini from guinea pig pancreas.

Authors:  R T Jensen; G F Lemp; J D Gardner
Journal:  J Biol Chem       Date:  1982-05-25       Impact factor: 5.157

3.  Characterization of cholecystokinin receptors on rat pancreatic membranes.

Authors:  R W Steigerwalt; J A Williams
Journal:  Endocrinology       Date:  1981-11       Impact factor: 4.736

Review 4.  Regulation of pancreatic growth.

Authors:  U R Fölsch
Journal:  Clin Gastroenterol       Date:  1984-09

5.  Evidence for a direct interaction between the penultimate aspartic acid of cholecystokinin and histidine 207, located in the second extracellular loop of the cholecystokinin B receptor.

Authors:  S Silvente-Poirot; C Escrieut; C Galès; J A Fehrentz; A Escherich; S A Wank; J Martinez; L Moroder; B Maigret; M Bouisson; N Vaysse; D Fourmy
Journal:  J Biol Chem       Date:  1999-08-13       Impact factor: 5.157

6.  A new probe for affinity labelling pancreatic cholecystokinin receptor with minor modification of its structure.

Authors:  D Fourmy; P Lopez; S Poirot; J Jimenez; M Dufresne; L Moroder; S P Powers; N Vaysse
Journal:  Eur J Biochem       Date:  1989-11-06

7.  Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.

Authors:  D Gully; D Fréhel; C Marcy; A Spinazzé; L Lespy; G Neliat; J P Maffrand; G Le Fur
Journal:  Eur J Pharmacol       Date:  1993-02-23       Impact factor: 4.432

8.  Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy.

Authors:  R Henderson; J M Baldwin; T A Ceska; F Zemlin; E Beckmann; K H Downing
Journal:  J Mol Biol       Date:  1990-06-20       Impact factor: 5.469

9.  Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor.

Authors:  A de Weerth; J R Pisegna; K Huppi; S A Wank
Journal:  Biochem Biophys Res Commun       Date:  1993-07-30       Impact factor: 3.575

10.  Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor.

Authors:  C D Ulrich; I Ferber; E Holicky; E Hadac; G Buell; L J Miller
Journal:  Biochem Biophys Res Commun       Date:  1993-05-28       Impact factor: 3.575

View more
  13 in total

1.  Probing a model of a GPCR/ligand complex in an explicit membrane environment: the human cholecystokinin-1 receptor.

Authors:  Jérôme Hénin; Bernard Maigret; Mounir Tarek; Chantal Escrieut; Daniel Fourmy; Christophe Chipot
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

2.  Processing of proaugurin is required to suppress proliferation of tumor cell lines.

Authors:  Akihiko Ozawa; Adam N Lick; Iris Lindberg
Journal:  Mol Endocrinol       Date:  2011-03-24

3.  Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.

Authors:  Maoqing Dong; Ashton M Vattelana; Polo C-H Lam; Andrew J Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; David R Haines; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2014-10-15       Impact factor: 4.436

4.  Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction.

Authors:  Maoqing Dong; Xi-Qin Ding; Scott E Thomas; Fan Gao; Polo C-H Lam; Ruben Abagyan; Laurence J Miller
Journal:  Biochemistry       Date:  2007-03-24       Impact factor: 3.162

5.  Exploring the binding pocket for pyridopyrimidine ligands at the CCK1 receptor by molecular docking.

Authors:  Amel Toumi-Maouche; Boubekeur Maouche; Safia Taïri-Kellou; Salima El-Aoufi; Mercedes Martín-Martínez; Rosario González-Muñiz; Daniel Fourmy; Bernard Maigret
Journal:  J Mol Model       Date:  2008-02-20       Impact factor: 1.810

6.  Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.

Authors:  Kaleeckal G Harikumar; Fan Gao; Delia I Pinon; Laurence J Miller
Journal:  Biochemistry       Date:  2008-08-13       Impact factor: 3.162

7.  Cholecystokinin 1 receptor modulates the MEKK1-induced c-Jun trans-activation: structural requirements of the receptor.

Authors:  Géraldine Ibarz; Catherine Oiry; Eric Carnazzi; Philippe Crespy; Chantal Escrieut; Daniel Fourmy; Jean Claude Galleyrand; Didier Gagne; Jean Martinez
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

8.  Tyrosine modification enhances metal-ion binding.

Authors:  Graham S Baldwin; Michael F Bailey; B Philip Shehan; Ioulia Sims; Raymond S Norton
Journal:  Biochem J       Date:  2008-11-15       Impact factor: 3.857

Review 9.  Structural basis of cholecystokinin receptor binding and regulation.

Authors:  Laurence J Miller; Fan Gao
Journal:  Pharmacol Ther       Date:  2008-05-11       Impact factor: 12.310

10.  Flexibility and extracellular opening determine the interaction between ligands and insect sulfakinin receptors.

Authors:  Na Yu; Moises João Zotti; Freja Scheys; Antônio S K Braz; Pedro H C Penna; Ronald J Nachman; Guy Smagghe
Journal:  Sci Rep       Date:  2015-08-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.